Bioxytran Reports 90% Day-5 Viral Clearance for ProLectin-M in Phase 1b/2a COVID-19 Study
BIXT sits 32% above its 52-week low of $0.034.
Summary
Bioxytran announced positive Phase 1b/2a clinical trial results for its antiviral drug ProLectin-M in mild to moderate COVID-19, demonstrating statistically significant earlier viral clearance and a favorable safety profile.
Key Events · Product Development and Regulatory · BIXT
-
Positive Phase 1b/2a Clinical Results
Bioxytran reported positive results from a randomized, double-blind, placebo-controlled Phase 1b/2a study of oral ProLectin-M in hospitalized patients with mild to moderate COVID-19.
-
Statistically Significant Viral Clearance
The highest dose of ProLectin-M (16,800 mg/day) achieved 90% non-detectable viral shedding by Day 5, significantly higher than the 20% observed in the placebo group (p=0.001).
-
Favorable Safety Profile
ProLectin-M was well tolerated at all evaluated dose levels, with no serious adverse events or treatment-related discontinuations.
-
Differentiated Antiviral Mechanism
ProLectin-M is designed to target galectins, blocking viral entry mechanisms, representing a novel antiviral strategy with potential applicability across multiple viral infections.
Analysis · BIXT · Life Sciences
This filing provides strong positive clinical data for Bioxytran's lead drug candidate, ProLectin-M, specifically in the context of COVID-19. The statistically significant 90% viral clearance by Day 5 at the highest dose, compared to placebo, is a critical indicator of efficacy. For a clinical-stage biotechnology company with a small market capitalization, such positive trial results are highly impactful, validating its carbohydrate-based therapeutic approach and supporting further development. This news builds on previous positive results for ProLectin-M and could significantly enhance investor confidence and the drug's commercial prospects.
At the time of this filing, BIXT was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.03 to $0.23. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.